The Zacks Analyst Blog Highlights: ExxonMobil, AT&T, Barclays, UnitedHealth and Lennar

Shutterstock photo

For Immediate Release

Chicago, IL - April 17, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ExxonMobil XOM , AT&T T , Barclays BCS , UnitedHealth UNH and Lennar LEN .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Monday's Analyst Blog:

Top Research Reports for ExxonMobil, AT&T and Barclays

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil, AT&T and Barclays. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see  all of  today's research reports here >>>

ExxonMobil 's shares have underperformed the Zacks Integrated Oil industry (-4.6% vs. +14.5%) as well as peer Chevron (+12.9%) over the last one year. However, Exxon Mobil has a leading position in the energy industry owing to the size and diversity of its asset base, both in terms of business mix and geographical footprint. With a stable cash position, the company's balance sheet is one of the best in the industry.

The Zacks analyst likes the integrated energy firm's decision to combine its refining & marketing businesses. This will allow the company to take better decisions and boost performance. ExxonMobil will generate more cashflow from downstream activities, also helping it counter the volatility in its upstream business.

However, the company's rising exploration expenses are a concern. On top of that, Exxon Mobil's exit from a joint venture in Russia will hurt cashflow.

(You can  read the full research report on ExxonMobil here >>> ).

Shares of AT&T have decreased -12.8% in the last year, underperforming the Zacks Wireless National industry's fall of -10.8%. However, AT&T is gearing up to launch the first standards-based mobile 5G services to consumers in multiple U.S. markets by the end of 2018.

Moreover, the Zacks analyst thinks the company is likely to immensely benefit from its long-pending merger with Time Warner Inc., with the combined entity expected to become a major player in the consolidated telecom-media space. Although the matter remains subjudice, the company is likely to go on the offensive to seek a verdict in its favor.

However, AT&T's profitability has been hurt with spectrum crunch in a saturated wireless market. In addition, the company's wireline division is struggling with persistent losses in access lines due to competitive pressure from voice-over-Internet protocol service providers and aggressive triple-play offerings by cable firms. These are weighing on AT&T's revenues and margins.

(You can  read the full research report on AT&T here >>> ).

Barclays 's shares have outperformed the Zacks Foreign Banks industry over the last six months, with BCS shares up +21.2% vs. +0.1% gain for the industry. The company has surpassed the Zacks Consensus Estimate for earnings in only one of the trailing four quarters. Its restructuring and business simplifying efforts (including ring-fencing) have ended successfully and will likely continue to result in decrease in expenses.

Also, driven by these efforts, the company intends to enhance capital deployment activities as profitability improves going forward. However, the bank has been facing pressure on revenues owing to weak capital market performance, low interest rates and uncertainty related to Brexit.

Further, litigation matters remain a near-term concern. In fact, settlement of the U.S. mortgage lawsuit for $2 billion will hurt its first quarter 2018 results.

(You can  read the full research report on Barclays here >>> ).

Other noteworthy reports we are featuring today include UnitedHealth and Lennar.

Investor Alert: Breakthroughs Pending

A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.

Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.

Click here to see them >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AT&T Inc. (T): Free Stock Analysis Report

Barclays PLC (BCS): Free Stock Analysis Report

Lennar Corporation (LEN): Free Stock Analysis Report

UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report

Exxon Mobil Corporation (XOM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Stocks
Referenced Symbols: T , BCS , LEN , UNH , XOM

More from Zacks.com




Equity Research

Research Brokers before you trade

Want to trade FX?